

Europe - UK (BST): 15:00 to 18:45 • Eastern (EDT): 10:00 to 13:45 • Central (CDT): 09:00 to 12:45 • Pacific (PDT): 07:00 to 10:45

The timetable below is listed in Europe-UK time (BST)

DAY 1 **FRIDAY September 24th, 2021**

15:00 to 15:05

Opening Remarks

I. McInnes

15:05 to 15:25

Plenary - Inspiring Change

Presenter: I. McInnes + Special guest: R. Fosbury

Objectives:

- **Inspire** delegates during this aspirational opening of the meeting
- **Discuss** what 'thinking outside the box' can do to transform best practice

15:25 to 15:30

Break

15:30 to 16:25

Parallel Workshops (Choice of Workshop)



Teamwork to Effectively Manage SpA

Faculty: D. Elewaut, M. Gooderham, T. Orchard, A. Ramanan

Objectives:

- **Discuss** how multiple disciplines can work together to provide better patient care
- **Identify** best practices for successful collaboration between specialists to better diagnose and manage uveitis, psoriasis, IBD, and pain in patients with SpA
- **Recognize** opportunities to include patients as part of the team and empower them to participate in decisions about their own care



Optimizing Treatment Strategies in RA

Faculty: R. Caporali, E. Mysler, J. Pope

Objectives:

- **Discuss** specific RA treatments based on their individual efficacy and safety data, including csDMARDs, tsDMARDs, TNFi, JAKi, and IL-6i
- **Understand** the importance of attaining remission for all patients and that it is an achievable goal
- **Consider** patient characteristics when optimizing treatment choices for your RA patients, such as age, comorbidities, and previous treatment choices



How to Be a Better Doctor

Faculty: E. Nikiphorou, B. Ohata, T. Vlieland

Objectives:

- **Apply** telemedicine in the management of rheumatic disease, focusing on the delivery of care and how to better interact with patients in a virtual environment
- **Outline** principles/strategies to effectively communicate with patients that lead to improved patient satisfaction and better outcomes
- **Recognize** the importance of shared decision-making between patients and rheumatologists for optimizing treatment outcomes



Optimizing Benefit Risk

Faculty: G. Burmester, K. Hyrich

Objectives:

- **Describe** the current sources of safety data to determine the benefits and risks of different treatment options
- **Review**
 - the serious infection risk considerations with advanced therapies (incl. HZ and COVID-19)
 - appropriateness of different therapies in patients with IMiDs and cardiovascular disease or risk factors (incl. MACE and VTE)
 - the malignancy risk of a patient starting advanced therapies
- **Define** strategies to mitigate these risks
- **Discuss** how to apply the shared decision-making process to engage patients in determining the benefits and risks of different therapeutic options

16:25 to 16:35

Break

16:35 to 16:55

Plenary - Are all JAKs Created Equal?

Presenter: E. Choy

Objectives:

- **Describe** the non-clinical differences between JAK inhibitors, including structure, potency of JAK isozymes, and selectivity profiles
- **Understand** how these different characteristics may impact clinical considerations for use (e.g., potential drug interactions, requirements for dose adjustment in renal and hepatic impairment)
- **Discuss** how the pharmacological differences between JAKi require each one to be assessed individually based on its own unique benefit-risk profile

16:55 to 17:00

Break

17:00 to 17:55

Parallel Workshops

Repeat of the above workshops, please proceed with a second choice

17:55 to 18:00

Closing Remarks

I. McInnes

18:00 to 18:30

Meet the Experts

All Faculty – I. McInnes, D. Aletaha, X. Baraliakos, M. Buch, G. Burmester, F. Buttgerit, R. Caporali, E. Choy, J. Curtis, L. Eder, D. Elewaut, C. Edwards, J. Galloway, M. Gooderham, K. Hyrich, E. Mysler, E. Nikiphorou, B. Ohata, T. Orchard, J. Pope, A. Ramanan, S. Rohekar, A. Rubbert-Roth, E. Thomson, F. Van den Bosch, T. Vlieland

Please click on an icon **HERE** to download a reminder to your calendar



DAY 2 **SATURDAY September 25th, 2021**

15:00 to 15:05

Opening Remarks

I. McInnes

15:05 to 15:25

Plenary - Is 2>1? Combination vs Monotherapy

Presenter: J. Galloway

Objectives:

- **Describe** the pros and cons of combination versus monotherapy in the management of RA
- **Review** the potential polypharmacy burden in RA patients with and without complex comorbidities
- **Determine** if monotherapy or combination therapy is ideal for the patient seen in clinical practice

15:25 to 15:30

Break

15:30 to 16:25

Parallel Workshops (Choice of Workshop)



Improving Outcomes in RA

Faculty: D. Aletaha, M. Buch

Objectives:

- **Describe** the key barriers and facilitators to implementing an effective treat-to-target (T2T) approach in RA
- **Review** potential definitions of treatment target(s) from the perspective of the HCP and patient, and understand their advantages/disadvantages
- **Discuss** best practices for patient-centric and holistic implementation of T2T recommendations in clinical practice




Optimizing Treatment Strategies in SpA

Faculty: X. Baraliakos, L. Eder, S. Rohekar, F. Van den Bosch

Objectives:

- **Practice** shared decision-making by involving patients in decisions about their disease management to personalize treatment
- **Identify and monitor** treatment targets/goals in SpA in order to optimize long-term outcomes and health-related quality of life
- **Assess** existing and emerging treatments that may be appropriate for patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA)




Difficult to Treat Cases. Beyond Evidence

Faculty: F. Buttgerit, I. McInnes

Objectives:

- **Debate and contrast** different treatment approaches for a patient weighing the benefits and risks of glucocorticoids for patients with RA and SpA
- **Discuss** how to choose an optimal treatment taking into consideration various factors for complex patients
- **Consider** a management strategy that looks beyond the evidence, when a standard approach is not effective



Rheum Post COVID

Faculty: J. Curtis, C. Edwards, A. Rubbert-Roth

Objectives:

- **Recognize** a patient's individual risk factors for poor outcomes to COVID-19 and provide evidence-based recommendations to reduce their risk
- **Address** common rheumatology clinical issues during the COVID-19 pandemic
- **Explain** the COVID-19 vaccine recommendations for rheumatology patients and practical immunization strategies (e.g. DMARD adjustment, vaccine hesitancy)
- **Review** guidelines and strategies for managing rheumatology patients in the post-COVID-19 setting

16:25 to 16:35

Break

16:35 to 16:55

Plenary - COVID Unplugged

Presenter: J. Curtis, A. Rubbert-Roth, E. Thomson

Objectives:

- **Review** the current COVID-19 pandemic trajectory globally, and the possible impact on patients in practice
- **Describe** the current COVID-19 vaccine recommendations for rheumatology patients
- **Develop** practical strategies for managing rheumatology patients in the post-COVID-19 world

16:55 to 17:00

Break

17:00 to 17:55

Parallel Workshops

Repeat of the above Workshops, please proceed with a second choice

17:55 to 18:15

Plenary - Dual AI Duel

Presenter: I. McInnes, B. Mesko

Objectives:

- **Discuss** the growing role of artificial intelligence (AI) in healthcare as a resource for clinical decision-making
- **Understand** the current capabilities and limitations of AI in healthcare and future direction

18:15 to 18:30

Closing Remarks

I. McInnes

Please click on an icon **HERE** to download a reminder to your calendar

